FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1739-1742 April 20, 2006 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network PubMed Citation

There is good reason that treatment of the acute respiratory distress syndrome (ARDS) with corticosteroids has been a much-studied subject. In response to a number of serious underlying events, such as sepsis, inhalation of gastric contents, and multiple trauma, the body reacts with acute inflammation of the lung parenchyma — a process that is characterized by increased vascular permeability, extravasation of plasma, and leukocyte infiltration; this combination of events is known as ARDS. This illness has an early acute phase that affects all patients; a variable fraction have a late phase, characterized by pulmonary fibrosis. Management of either phase of . . . [Full Text of this Article]

Source Information

From the University of Geneva, Geneva.

This article has been cited by other articles:

• McGee, S., Hirschmann, J. (2008). Use of Corticosteroids in Treating Infectious Diseases. Arch Intern Med 168: 1034-1046 [Abstract] [Full Text]  
• Peter, J. V., John, P., Graham, P. L, Moran, J. L, George, I. A., Bersten, A. (2008). Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 336: 1006-1009 [Abstract] [Full Text]